Skip to main content
IBRX logo

IBRX

ImmunityBio Inc

$6.03

8.30%

Trade Ideas Performance

Latest Closed Trade Idea

$6.03

8.30%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

4

Social

4

About

Events of ImmunityBio Inc (IBRX)

ImmunityBio's stock has been influenced by several events over the past six months (May 2026 - November 2026). On November 5, 2026, the first patients in Europe received ANKTIVA treatment, though the stock moved below its 50-day moving average and Momentum Indicator, signaling bearish trends. In October 2026, the FDA expanded ANKTIVA's approval to include papillary-only BCG-unresponsive non-muscle invasive bladder cancer. On October 28, 2026, the 10-day moving average crossed bearishly below the 50-day moving average. ImmunityBio announced Q2 2026 earnings on August 4, 2026, reporting record net product revenue of $50.7 million, a 92% increase year-over-year and the eighth consecutive quarter of sequential revenue growth. In July 2026, the United Arab Emirates granted marketing authorization for ANKTIVA across BCG-unresponsive NMIBC and metastatic NSCLC. On March 31, 2026, the company secured $75 million in non-dilutive financing and reduced debt by $25 million through a conversion by Nant Capital. A securities fraud investigation was announced on March 30, 2026, following a Bloomberg report on March 24, 2026, about an FDA Warning Letter regarding inaccurate claims made by the Executive Chairman about ANKTIVA on a podcast, which caused a 21.12% stock price fall. The stock jumped 40% on February 19, 2026, due to positive regulatory and clinical updates, including European conditional marketing authorization for ANKTIVA and new Phase 2 trials for CAR-NK cell therapy programs. However, on February 13, 2026, the stock dropped 10.2% after a law firm announced an investigation into potential securities fraud. In February 2026, the European Commission granted conditional marketing authorization for ANKTIVA. On February 23, 2026, the company reported full-year 2025 financial and operational highlights, including approximately $113 million in net product revenue for ANKTIVA (a 700% increase year-over-year) and an expanded global regulatory footprint to 33 countries. In January 2026, the Saudi Food and Drug Authority (SFDA) granted accelerated approval for ANKTIVA in BCG-unresponsive NMIBC CIS and conditional accelerated approval for metastatic NSCLC.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)